{"entity":{"id":"idea-bio2-ai-sarcopenia-from-ct","kind":"idea","name":"Read muscle loss automatically from scans patients already have","aka":[],"tldr":"Every staging scan contains a precise measure of muscle mass that nobody looks at. Software could report it automatically and flag patients heading for wasting.","summary":"Automated segmentation of skeletal muscle at the third lumbar vertebra is accurate and fast, and low muscle mass predicts chemotherapy toxicity, surgical complications and survival across tumour types. The measurement is free because the scans already exist; the missing pieces are automated reporting into the record and a defined action when the value is low.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)","url":"https://doi.org/10.1016/S1470-2045(10)70218-7"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["radiology-ai-screening","ct","geriatric-assessment","exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-cachexia-supportive","b-ai-validation","b-toxicity-qol"],"keyPapers":["paper-fearon-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Automated muscle metrics reported with every staging scan identify high-risk patients earlier than weight loss criteria, and triggering a supportive care pathway on that flag improves treatment completion rates.","rationale":"Opportunistic imaging biomarkers have already been adopted for bone density and coronary calcium from routine scans. Cachexia is currently diagnosed late, by weight loss that has already occurred, when reversal is hardest.","test":"Deploy automated segmentation in one centre and randomise by clinic to flag-triggered referral versus usual care; endpoints are treatment completion, dose intensity and hospital admissions.","maturity":"preclinical-evidence","actor":"data","cost":"small","horizonYears":3},"route":"/ideas/idea-bio2-ai-sarcopenia-from-ct/","neighbours":{"technology":[{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/"},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/"},{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/"},{"id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/"},{"id":"muscle-recovery-after-cancer-treatment","kind":"technology","name":"Muscle and strength after treatment: sarcopenia, cachexia and what rebuilds","route":"/technologies/muscle-recovery-after-cancer-treatment/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"paper":[{"id":"paper-fearon-lancet-oncol","kind":"paper","name":"Definition and classification of cancer cachexia: an international consensus","route":"/key-papers/paper-fearon-lancet-oncol/"}],"term":[{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/"},{"id":"sarcopenia","kind":"term","name":"Sarcopenia","route":"/terms/sarcopenia/"}]}}